Desert Partners, L.P. v. USG Corp.

686 F. Supp. 1289, 1988 U.S. Dist. LEXIS 3963, 1988 WL 51752
CourtDistrict Court, N.D. Illinois
DecidedApril 28, 1988
Docket87C9399, 87C9455 and 88C1813
StatusPublished
Cited by6 cases

This text of 686 F. Supp. 1289 (Desert Partners, L.P. v. USG Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Desert Partners, L.P. v. USG Corp., 686 F. Supp. 1289, 1988 U.S. Dist. LEXIS 3963, 1988 WL 51752 (N.D. Ill. 1988).

Opinion

MEMORANDUM OPINION AND ORDER

HOLDERMAN, District Judge:

Plaintiffs Desert Partners, L.P., Desert Partners Acquisition, Inc. (collectively “Desert Partners”), and Morris M. Cottle 1 bring this motion for preliminary injunction against defendant USG Corporation (“USG”) and its Board of Directors. 2 Desert Partners requests the court to enjoin USG from implementing its poison pill. For the following reasons, the motions for preliminary injunction are DENIED.

BACKGROUND 3

USG Corporation is a publicly held Delaware corporation with its executive offices and principal place of business in Chicago, Illinois. USG is a diversified manufacturer of building materials. According to Michael J. Zimmerman of Salomon Brothers, Inc., USG’s financial advisor, USG has enjoyed a relatively prosperous existence over the past decade. Its growth rate in earnings per share ranks fourteenth among all Fortune 500 companies. (Zimmerman *1291 Aff. II2). The 1987 Fortune Magazine Directory ranked USG seventh among Fortune 500 companies in return on stockholder’s equity. Id. Moreover, USG stockholders have benefited from USG’s performance. Over the past five years, the price of the company’s shares on the New York Stock Exchange appreciated approximately 191 percent. In contrast, the S & P 500 average increased only 50 percent. Id.

Despite its prosperity, Mr. Zimmerman indicates that the price of USG stock “has not always reflected the true value of the company.” (Zimmerman Aff. II3). As a result, USG’s management has adopted a number of defensive strategies to minimize the likelihood that USG will fall prey to a hostile takeover or some other attempt to gain control of the company. 4 In this motion, Desert Partners challenges USG’s use of its Preferred Share Purchase Rights Plan, or “poison pill,” which the Board adopted on March 20, 1986.

USG’s poison pill enables the Board to create and distribute one “Right” for each share of USG common stock. Under the terms of the Plan, ten days after an entity 1) acquires 20 percent or more of USG’s shares or 2) announces an offer to acquire 30 percent or more of USG’s shares, the Rights become exercisable and the holder of each Right may purchase 1/10 of a share of preferred stock for $200. The “poisonous” effect of the pill occurs when USG is subsequently involved in a merger or other business combination in the event of a subsequent merger, a holder may purchase either $400 worth of USG stock for $200 (the “flip-in” provision) or $400 worth of the acquiror’s stock for $200 (the “flip-over” provision), depending upon the structure of the merger. Because the potential acquiror may not exercise these rights, USG shareholders can dilute the value of the acquiror’s ownership by buying additional common shares at a 50 percent discount.

Desert Partners began accumulating shares of USG in July, 1987. 5 Between July 29 and October 5, 1987, Desert Partners acquired more than 5 million shares of USG (9.93 percent of all outstanding shares) for an average price of approximately $45 per share. In late October, 1987 Desert Partners announced its intention to acquire control of USG and met with USG representatives to propose a negotiated transaction. The Company responded to Desert Partners’ overtures on October 29, 1987 by filing an action in this court seeking to enjoin Desert Partners from acquiring any additional shares of USG stock. 6 In addition, USG issued a press release stating that it had no interest in participating in a negotiated transaction with Desert Partners.

Desert Partners continued its attempt to negotiate a transaction with USG. On February 24,1988 Desert Partners notified the USG Board that Desert Partners remained interested in acquiring USG and in consummating a negotiated acquisition. Desert *1292 Partners presented USG managers with a proposal to acquire 21,500,000 USG shares for $42 per share in cash and the remaining shares for $42 principal amount per share in subordinated debt securities. USG Chairman of the Board Robert J. Day responded that the Board had no interest in discussing Desert Partners’ proposal. Desert Partners thereafter made its tender offer directly to USG shareholders.

On March 1, 1988 Desert Partners commenced a two-tiered tender offer for USG shares. On April 11, 1988 Desert Partners amended the terms of its offer and extended its expiration date to April 29, 1988. 7 The first tier of the amended offer consists of an offer to purchase up to 39 million shares (including the associated poison pill Rights) for $42 per share. If Desert Partners consummates the offer’s first tier, Desert Partners will own approximately 85 percent of USG’s outstanding shares of common stock. In the second tier of the amended offer, Desert Partners proposes to exchange each remaining USG share for securities having an aggregate value of at least $42 per share on a fully distributed basis. Although Desert Partners has not disclosed with certainty the nature of the second tier securities it intends to exchange, the initial offer suggests that Desert Partners will offer a combination of debt securities and warrants to purchase additional stock to each second tier shareholder. (PX at 35). 8

On March 8, 1988 the USG Board voted to recommend that shareholders reject Desert Partners’ offer, concluding that the offer was “wholly inadequate, coercive and not in the best interests of the Corporation and its stockholders.” (PX 4 at 2). In its Schedule 14d-4 filing, the Board stated that it took into account several factors in reaching this conclusion:

1) the Board’s familiarity with USG’s business, financial condition, business strategy and future prospects;
2) the Board’s belief that the offer does not reflect USG’s long-term value;
3) USG’s management presentations concerning USG’s financial performance and potential;
4) the presentation of USG’s financial advisors and their oral opinion that the price of $42 per share was inadequate;
5) the presentations of USG’s legal counsel concerning the Board’s obligations under both Delaware corporate law and the federal securities laws;
6) the fact that the offer is a “two-tiered, coercive, front-end loaded offer” for USG shares followed by a “back-end merger for ‘junk bonds’ and warrants purportedly worth $42 per share;” and
7) the Board’s belief that it is in the best interests of the corporation for USG to pursue a course designed to assure its continued corporate independence.

(PX 4 at 3). As a result of this conclusion, the Board decided not to redeem the shareholder Rights under the poison pill. (Clark Dep. at 71).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Diginet, Inc. v. Western Union ATS, Inc.
759 F. Supp. 1285 (N.D. Illinois, 1991)
Norman v. Johnson
739 F. Supp. 1182 (N.D. Illinois, 1990)
Air Line Pilots Ass'n, International v. UAL Corp.
717 F. Supp. 575 (N.D. Illinois, 1989)
A. Copeland Enterprises, Inc. v. Guste
706 F. Supp. 1283 (W.D. Texas, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
686 F. Supp. 1289, 1988 U.S. Dist. LEXIS 3963, 1988 WL 51752, Counsel Stack Legal Research, https://law.counselstack.com/opinion/desert-partners-lp-v-usg-corp-ilnd-1988.